{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:38:48Z","timestamp":1790401128973,"version":"4.1.0"},"reference-count":68,"publisher":"European Respiratory Society (ERS)","issue":"176","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2025,3,30]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Despite the clinical benefits, the administration of biologics in asthma is not without adverse effects. However, there is a lack of information on the safety profile, particularly in children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To provide a systematic review of the range of reported adverse events (AEs) of biologic treatments approved for paediatric asthma (Xolair, Nucala, Dupixent, Fasenra and Tezspire).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>\n                      Databases (MEDLINE, CENTRAL, Scopus and Web of Science) and one registry (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/\">ClinicalTrials.gov<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection<\/jats:title>\n                    <jats:p>This review included randomised clinical trials, prospective clinical studies, real-world studies, exploratory studies, registry analyses, case series and case reports, which met predefined inclusion criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction<\/jats:title>\n                    <jats:p>Study characteristics and AEs were extracted into predefined forms and then summarised in terms of their frequency and study duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 45 reports and 13 clinical trials met the inclusion criteria for data evaluation, of which eight studies were placebo-controlled. Overall, paediatric asthma patients\u2019 most frequently reported AEs were headache, injection site reactions, upper respiratory tract infections, pyrexia and urticaria. The systematic analysis revealed a similar safety profile of the biologics to that reported on the product labels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Limitations<\/jats:title>\n                    <jats:p>The small number of paediatric patients, missing placebo control groups, variant definitions of AEs and a lack of statistical evaluation limited the validation of specific AEs to individual biologics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this systematic review, no new safety concerns regarding the use of biologics in paediatric asthma were identified, even after an observation period of up to 7\u2005years. In order to record rare side-effects and possible long-term consequences, further data from paediatric study cohorts are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/16000617.0269-2024","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:25:17Z","timestamp":1750220717000},"page":"240269","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety of biologics for the treatment of asthma in children and adolescents: a systematic review"],"prefix":"10.1183","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8696-1675","authenticated-orcid":false,"given":"Elisa","family":"Wirthgen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susann","family":"Quickert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Weitzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Salewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4480-1312","authenticated-orcid":false,"given":"Manfred","family":"Ballmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"2025061801251203000_34.176.240269.1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00246"},{"key":"2025061801251203000_34.176.240269.2","unstructured":"Global Initiative for Asthma (GINA) . Global Strategy for Asthma Management and Prevention. 1995. Available from: https:\/\/ginasthma.org\/"},{"key":"2025061801251203000_34.176.240269.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.10.003"},{"key":"2025061801251203000_34.176.240269.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.01.002"},{"key":"2025061801251203000_34.176.240269.5","doi-asserted-by":"crossref","first-page":"100737","DOI":"10.1016\/j.waojou.2022.100737","article-title":"Risks and safety of biologics: a practical guide for allergists","volume":"16","author":"Sitek","year":"2023","journal-title":"World Allergy Organ J"},{"key":"2025061801251203000_34.176.240269.6","unstructured":"Peryer G , Golder S , Junqueira D , et al. Adverse events. In: Higgins JPT , Thomas J , Chandler J , et al. , eds. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). London, Cochrane, 2023; chapter 19."},{"key":"2025061801251203000_34.176.240269.7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"2025061801251203000_34.176.240269.8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2147\/JAA.S172338","article-title":"Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the phase IIIb ALIZE trial","volume":"11","author":"Zeitlin","year":"2018","journal-title":"J Asthma Allergy"},{"key":"2025061801251203000_34.176.240269.9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s41030-023-00245-9","article-title":"Effect of tezepelumab on the humoral immune response to seasonal quadrivalent influenza vaccination in patients with moderate to severe asthma: the phase 3b VECTOR study","volume":"10","author":"Cole","year":"2024","journal-title":"Pulm Ther"},{"key":"2025061801251203000_34.176.240269.10","unstructured":"US Food and Drug Administration . What is a serious adverse event? 2023. www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event Date last accessed: 24 April 2025."},{"key":"2025061801251203000_34.176.240269.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647"},{"key":"2025061801251203000_34.176.240269.12","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jclinepi.2017.04.023","article-title":"A new risk of bias checklist applicable to randomized trials, observational studies, and systematic reviews was developed and validated to be used for systematic reviews focusing on drug adverse events","volume":"86","author":"Faillie","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"2025061801251203000_34.176.240269.13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2017-110853"},{"key":"2025061801251203000_34.176.240269.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009705"},{"key":"2025061801251203000_34.176.240269.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.09.021"},{"key":"2025061801251203000_34.176.240269.16","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.2.e36"},{"key":"2025061801251203000_34.176.240269.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.09.008"},{"key":"2025061801251203000_34.176.240269.18","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S1081-1206(10)62175-8","article-title":"Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma","volume":"91","author":"Berger","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025061801251203000_34.176.240269.19","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00008115"},{"key":"2025061801251203000_34.176.240269.20","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.alit.2015.05.006","article-title":"Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy","volume":"64","author":"Odajima","year":"2015","journal-title":"Allergol Int"},{"key":"2025061801251203000_34.176.240269.21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2174\/1573398X13666170426094536","article-title":"Omalizumab in children with severe allergic asthma: the Italian real-life experience","volume":"13","author":"Licari","year":"2017","journal-title":"Curr Respir Med Rev"},{"key":"2025061801251203000_34.176.240269.22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.alit.2016.06.004","article-title":"Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma","volume":"66","author":"Odajima","year":"2017","journal-title":"Allergol Int"},{"key":"2025061801251203000_34.176.240269.23","first-page":"e115","article-title":"Clinical impact of omalizumab treatment in children with severe asthma: report of a local experience","volume":"117","author":"Giubergia","year":"2019","journal-title":"Arch Argent Pediatr"},{"key":"2025061801251203000_34.176.240269.24","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study","volume":"7","author":"Casale","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025061801251203000_34.176.240269.25","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/all.13678","article-title":"Omalizumab discontinuation in children with severe allergic asthma: an observational real-life study","volume":"74","author":"Deschildre","year":"2019","journal-title":"Allergy"},{"key":"2025061801251203000_34.176.240269.26","doi-asserted-by":"crossref","first-page":"e187430642206130","DOI":"10.2174\/18743064-v16-e2206130","article-title":"Real-life effectiveness of omalizumab in patients with severe allergic asthma: RELIEF study","volume":"16","author":"Al Ahmad","year":"2022","journal-title":"Open Respir Med J"},{"key":"2025061801251203000_34.176.240269.27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.alit.2021.01.001","article-title":"Real-life long-term safety and effectiveness of omalizumab in Japanese pediatric patients with severe allergic asthma: a post-marketing surveillance","volume":"70","author":"Nakamura","year":"2021","journal-title":"Allergol Int"},{"key":"2025061801251203000_34.176.240269.28","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3390\/children11020170","article-title":"Early assessment of efficacy and safety of biologics in pediatric allergic diseases: preliminary results from a prospective real-world study","volume":"11","author":"Caminiti","year":"2024","journal-title":"Children"},{"key":"2025061801251203000_34.176.240269.29","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.aller.2018.09.009","article-title":"\u2018Real-life\u2019 experience in asthmatic children treated with omalizumab up to six-years follow-up","volume":"47","author":"Folqu\u00e9","year":"2019","journal-title":"Allergol Immunopathol"},{"key":"2025061801251203000_34.176.240269.30","first-page":"100","article-title":"Experience of long-term omalizumab treatment for pediatric asthma in Astrakhan region","volume":"10","author":"Sergienko","year":"2020","journal-title":"Archiv Euromedica"},{"key":"2025061801251203000_34.176.240269.31","doi-asserted-by":"crossref","first-page":"1236798","DOI":"10.3389\/falgy.2023.1236798","article-title":"Therapeutic efficacy of omalizumab in children with moderate-to-severe allergic asthma combined with chronic sinusitis","volume":"4","author":"Chong","year":"2023","journal-title":"Front Allergy"},{"key":"2025061801251203000_34.176.240269.32","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2147\/JAA.S406628","article-title":"Real-world safety and effectiveness of omalizumab in moderate to severe allergic asthma patients in China: a post-authorization study","volume":"16","author":"Su","year":"2023","journal-title":"J Asthma Allergy"},{"key":"2025061801251203000_34.176.240269.33","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3390\/jpm13071068","article-title":"Long-term safety of omalizumab in children with asthma and\/or chronic spontaneous urticaria: a 4-year prospective study in real life","volume":"13","author":"Galletta","year":"2023","journal-title":"J Pers Med"},{"key":"2025061801251203000_34.176.240269.34","doi-asserted-by":"crossref","first-page":"182","DOI":"10.15586\/aei.v51i4.926","article-title":"Effects of omalizumab combined with budesonide formoterol on clinical efficacy, pulmonary function, immune function, and adverse reactions in children with moderate and severe allergic asthma","volume":"51","author":"Chen","year":"2023","journal-title":"Allergol Immunopathol"},{"key":"2025061801251203000_34.176.240269.35","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/pai.13484","article-title":"Omalizumab outcomes for up to 6\u2005years in pediatric patients with severe persistent allergic asthma","volume":"32","author":"Garc\u00eda","year":"2021","journal-title":"Pediatr Allergy Immunol"},{"key":"2025061801251203000_34.176.240269.36","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3390\/children8121141","article-title":"Clinical experience with anti-IgE monoclonal antibody (omalizumab) in pediatric severe allergic asthma \u2013 a Romanian perspective","volume":"8","author":"Berghea","year":"2021","journal-title":"Children"},{"key":"2025061801251203000_34.176.240269.37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2500\/aap.2019.40.4173","article-title":"Systemic reaction rates with omalizumab, subcutaneous immunotherapy, and combination therapy in children with allergic asthma","volume":"40","author":"Har","year":"2019","journal-title":"Allergy Asthma Proc"},{"key":"2025061801251203000_34.176.240269.38","first-page":"1764","article-title":"First experience with omalizumab in a child with severe persistent asthma in Turkey: case report","volume":"30","author":"Arga","year":"2010","journal-title":"Turk Klin J Med Sci"},{"key":"2025061801251203000_34.176.240269.39","first-page":"422","article-title":"Long term outcome of omalizumab therapy in childhood severe allergic asthma","volume":"76","author":"Daud","year":"2021","journal-title":"Med J Malaysia"},{"key":"2025061801251203000_34.176.240269.40","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-018-1019-9"},{"key":"2025061801251203000_34.176.240269.41","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fped.2019.00213","article-title":"Successful treatment with omalizumab in a child with asthma and urticaria: a clinical case report","volume":"7","author":"Sirufo","year":"2019","journal-title":"Front Pediatr"},{"key":"2025061801251203000_34.176.240269.42","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13052-019-0602-5","article-title":"Omalizumab in children with severe allergic disease: a case series","volume":"45","author":"Crisafulli","year":"2019","journal-title":"Ital J Pediatr"},{"key":"2025061801251203000_34.176.240269.43","doi-asserted-by":"crossref","first-page":"427","DOI":"10.5114\/ada.2021.107929","article-title":"Effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from Poland","volume":"38","author":"Sztafi\u0144ska","year":"2021","journal-title":"Postepy Dermatol Alergol"},{"key":"2025061801251203000_34.176.240269.44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40264-019-00870-x","article-title":"Exploratory study of signals for asthma drugs in children, using the EudraVigilance database of spontaneous reports","volume":"43","author":"Baan","year":"2020","journal-title":"Drug Saf"},{"key":"2025061801251203000_34.176.240269.45","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00149812"},{"key":"2025061801251203000_34.176.240269.46","doi-asserted-by":"publisher","DOI":"10.1111\/all.13302"},{"key":"2025061801251203000_34.176.240269.47","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0140-6736(22)01198-9","article-title":"Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"400","author":"Jackson","year":"2022","journal-title":"Lancet"},{"key":"2025061801251203000_34.176.240269.48","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2019.08.005","article-title":"Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype","volume":"144","author":"Gupta","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2025061801251203000_34.176.240269.49","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/ppul.24508","article-title":"Subcutaneous mepolizumab in children aged 6 to 11\u2005years with severe eosinophilic asthma","volume":"54","author":"Gupta","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"2025061801251203000_34.176.240269.50","doi-asserted-by":"crossref","first-page":"113","DOI":"10.15586\/aei.v49i5.466","article-title":"Steroid-sparing effect of mepolizumab in children with severe eosinophilic nonallergic asthma","volume":"49","author":"Tosca","year":"2021","journal-title":"Allergol Immunopathol"},{"key":"2025061801251203000_34.176.240269.51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106567"},{"key":"2025061801251203000_34.176.240269.52","doi-asserted-by":"crossref","first-page":"12","DOI":"10.15586\/aei.v51i5.877","article-title":"Time effect of dupilumab to treat severe uncontrolled asthma in adolescents: a pilot study","volume":"51","author":"Indolfi","year":"2023","journal-title":"Allergol Immunopathol"},{"key":"2025061801251203000_34.176.240269.53","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(23)00303-X","article-title":"Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study","volume":"12","author":"Bacharier","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2025061801251203000_34.176.240269.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.02.009"},{"key":"2025061801251203000_34.176.240269.55","doi-asserted-by":"crossref","first-page":"e14092","DOI":"10.1111\/pai.14092","article-title":"Benralizumab in children with severe eosinophilic asthma: pharmacokinetics and long-term safety (TATE study)","volume":"35","author":"Wedner","year":"2024","journal-title":"Pediatr Allergy Immunol"},{"key":"2025061801251203000_34.176.240269.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.07.038"},{"key":"2025061801251203000_34.176.240269.57","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.jaci.2016.12.953","article-title":"Cardiovascular and cerebrovascular events among patients receiving omalizumab: pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials","volume":"139","author":"Iribarren","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2025061801251203000_34.176.240269.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.12.024"},{"key":"2025061801251203000_34.176.240269.59","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90159-8"},{"key":"2025061801251203000_34.176.240269.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.12.1303"},{"key":"2025061801251203000_34.176.240269.61","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1965.03080150038007"},{"key":"2025061801251203000_34.176.240269.62","doi-asserted-by":"crossref","first-page":"S481","DOI":"10.1016\/S0091-6749(18)30571-2","article-title":"Definitions of anaphylaxis and anaphylactoid events","volume":"101","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"2025061801251203000_34.176.240269.63","first-page":"16","article-title":"Clinical data do not suggest a causal relationship between omalizumab therapy and cancer","volume":"2","author":"Fernandez","year":"2005","journal-title":"Proc Am Thorac Soc"},{"key":"2025061801251203000_34.176.240269.64","doi-asserted-by":"crossref","first-page":"100721","DOI":"10.1016\/j.waojou.2022.100721","article-title":"Omalizumab and cancer risk: current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps","volume":"15","author":"Bagnasco","year":"2022","journal-title":"World Allergy Organ J"},{"key":"2025061801251203000_34.176.240269.65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5827"},{"key":"2025061801251203000_34.176.240269.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.02.007"},{"key":"2025061801251203000_34.176.240269.67","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.anai.2024.05.014","article-title":"A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: a position paper of the American College of Allergy, Asthma and Immunology","volume":"133","author":"Lieberman","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025061801251203000_34.176.240269.68","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1164\/rccm.202210-1898LE","article-title":"Parasitic infections and biological therapies targeting type 2 inflammation: a VigiBase study","volume":"207","author":"Lifar","year":"2023","journal-title":"Am J Respir Crit Care Med"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0269-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:25:25Z","timestamp":1750220725000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0269-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":68,"journal-issue":{"issue":"176","published-online":{"date-parts":[[2025,6,18]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1183\/16000617.0269-2024"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0269-2024","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}